Description
ADCC-Enhanced anti-Alpha-synuclein (1H7) is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform.
Antibody Indication
Parkinson's Disease
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Alpha-synuclein antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Full Name
synuclein, alpha
Background
Alpha-synuclein is a member of the synuclein family, which also includes beta- and gamma-synuclein. Synucleins are abundantly expressed in the brain and alpha- and beta-synuclein inhibit phospholipase D2 selectively. SNCA may serve to integrate presynaptic signaling and membrane trafficking. Defects in SNCA have been implicated in the pathogenesis of Parkinson disease. SNCA peptides are a major component of amyloid plaques in the brains of patients with Alzheimer's disease. Four alternatively spliced transcripts encoding two different isoforms have been identified for this gene.
Alternative Names
SNCA; synuclein, alpha; PD1; NACP; PARK1; PARK4; Alpha-synuclei
Cellular Localization
Extracellular region or secreted, Nucleus
Involvement in Disease
Diseases associated with SNCA include Dementia, Lewy Body and Parkinson Disease 1, Autosomal Dominant.
Related Pathways
Its related pathways are Neuroscience and Parkinsons Disease Pathway.
Function
Neuronal proteins play a variety of roles in synaptic activity, such as the transport of synaptic vesicles and the subsequent regulation of neurotransmitter release. As a monomer, it participates in the extracellular secretion of synaptic vesicles by enhancing the initiation and fusion of vesicles and the expansion of extracellular fusion pores. Mechanically, it works by increasing the local Ca(2+) release of the microdomains, which is essential for enhancing atp-induced exocytosis. As a molecular chaperone in the state of polymembrane binding, together with cysteine chain protein--/DNAJC5, it assists the folding of synaptic fusion components called SNAREs (soluble NSF attachment protein receptors) on the presynaptic plasma membrane. The activity of this chaperone is important for maintaining normal snr complex assembly during aging. By being associated with the dopamine transporter (DAT1) to regulate its activity, it also plays a role in the regulation of dopamine neurotransmission.
Field of research
Neuroscience antibody
Post-translational modifications
Phosphorylated, predominantly on serine residues. Phosphorylation by CK1 appears to occur on residues distinct from the residue phosphorylated by other kinases. Phosphorylation of Ser-131 is selective and extensive in synucleinopathy lesions. In vitro, phhorylation at Ser-129 promoted insoluble fibril formation. Phosphorylated on Tyr-125 by a PTK2B-dependent pathway upon osmotic stress. Hallmark lesions of neurodegenerative synucleinopathies contain alpha-synuclein that is modified by nitration of tyrosine residues and possibly by dityrosine cross-linking to generated stable oligomers. Ubiquitinated. The predominant conjugate is the diubiquitinated form (By similarity). Acetylation at Met-1 seems to be important for proper folding and native oligomeric structure.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description
PRX002 is a monoclonal antibody for the potential treatment of Parkinson's disease and other related synucleinopathies. Treatment-emergent adverse events in greater than 5% of subjects were vessel puncture site pain, headache, viral infection, nausea, neutropenia, upper respiratory infection and pruritus. All PRX002-related adverse events were mild and no dose limiting toxicities were observed. No anti-drug antibody were detected.
Antibody Indication
Parkinson's Disease
